Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 4, 2025

Supplementary Figure S3 from METTL3 Promotes Gastric Cancer Progression via Modulation of FNTA-Mediated KRAS/ERK Signaling Activation

View Full Paper
Ask AI
Bookmark
Share

Authors

FHFangqi HuSZSong ZhangJCJie Chai

Discussion

Loading...

Member takes

Overview

Experimental analysis reveals METTL3 enhances gastric cancer progression via FNTA-mediated KRAS/ERK signaling activation, indicating its importance in cancer development.

Key Points

  • MAIN FINDING: METTL3 significantly promotes gastric cancer progression through the modulation of FNTA signaling.
  • KEY EVIDENCE: Experimental data show heightened KRAS/ERK signaling in cells with increased METTL3 levels.
  • APPROACH: Researchers utilized quantification analysis to assess the effects of METTL3 on FNTA and KRAS activation.
  • SIGNIFICANCE: Understanding METTL3's role could lead to novel therapeutic strategies in gastric cancer treatment.

Cite This Study

Hu et al. (2025) studied this question.

synapsesocial.com/papers/689a0f86e6551bb0af8d0985https://doi.org/10.1158/1541-7786.29819557
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplementary Figure S2 from METTL3 Promotes Gastric Cancer Progression via Modulation of FNTA-Mediated KRAS/ERK Signaling Activation2025
  2. 2Supplementary Figure S1 from METTL3 Promotes Gastric Cancer Progression via Modulation of FNTA-Mediated KRAS/ERK Signaling Activation2025
  3. 3Data from METTL3 Promotes Gastric Cancer Progression via Modulation of FNTA-Mediated KRAS/ERK Signaling Activation2025
  4. 4Supplementary Figure S9 from TERC Stimulates Fatty Acid Metabolism to Promote Bladder Cancer Progression2025
  5. 5Figure S3 from Loss of LGR5 through therapy-induced downregulation or gene ablation is associated with resistance and enhanced MET-STAT3 signaling in colorectal cancer cells2024